Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | GLA | P06280 | 3/20 | 0.31 |
| ▸ | PKM | P14618 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936546 | 0.84 | USP7 (0.34) | KDM4EALDH1A1GLAPKMHPGD | |
| SCHEMBL3936654 | 0.84 | HTT (0.32) | KDM4EALDH1A1GLAPKMHPGD | |
| SCHEMBL3939388 | 0.83 | CTSS (0.30) | KDM4EALDH1A1GLAPKMHPGD | |
| SCHEMBL3936568 | 0.83 | KDM4E (0.32) | KDM4EALDH1A1GLAPKMHPGD | |
| SCHEMBL3943684 | 0.80 | GSK3B (0.35) | KDM4EALDH1A1HPGDP2RX3LMNA | |
| SCHEMBL3944613 | 0.79 | KDM4E (0.33) | KDM4EALDH1A1GLAPKMHPGD | |
| SCHEMBL13843279 | 0.78 | KMT2A (0.34) | KDM4EALDH1A1GLAPKMHPGD | |
| SCHEMBL13843377 | 0.76 | KDM4E (0.39) | KDM4EALDH1A1GLAPKMHPGD | |
| SCHEMBL13843280 | 0.73 | KDM4E (0.34) | KDM4EALDH1A1GLAPKMHPGD | |
| SCHEMBL4328664 | 0.69 | P2RX3 (0.30) | P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | TEIJIN LIMITED (JP) | 2005-12-15 | — | — | US | disclosed |
| EP-1477489-A1 | PYRROLOPYRIMIDINE DERIVATIVES | TEIJIN LIMITED (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | GSK3B, GSK3A, GSKIP | KDM4E 1378/4885ALDH1A1 2709/4885GLA 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.